Drug Trial Radar · NCT00000894
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
Last checked: Nov 19, 2026Latest source record: Feb 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Not stated
Primary completion
Jun 2000
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 4
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in patients who have AIDS complicated by CMV (cytomegalovirus) retinitis. Cidofovir needs to be compared to ganciclovir to determine the best way to treat CMV retinitis.
Conditions
- Cytomegalovirus Retinitis
- HIV Infections
Interventions
CidofovirDrug
ProbenecidDrug
GanciclovirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California
UCLA CARE Ctr
Los Angeles, California
Univ of Miami / Bascom Palmer Eye Institute
Miami, Florida
Emory Eye Clinic
Atlanta, Georgia
Northwestern Univ / SOCA
Chicago, Illinois
Charity Hosp / Tulane Univ Med School
New Orleans, Louisiana
Johns Hopkins Hosp
Baltimore, Maryland
Cornell Univ Med Ctr
New York, New York
New York Hosp / Cornell Med Ctr
New York, New York
Univ of North Carolina
Chapel Hill, North Carolina
Julio Arroyo
West Columbia, South Carolina
Univ of Texas Galveston
Galveston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.